Research. Discover. Cure.

The project brings together 25 partners across 8 countries and incorporates Almirall, Sanofi, and other pharmaceutical companies to provide feedback and evaluate the practical usefulness of the platform in industrial settings.

Gate2Brain, an IRB Barcelona spin-off, signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake in the company.
 

The financing supports Ona Therapeutics, an IRB Barcelona and ICREA spin-off, in its transition to a clinical-stage company.

HelixAI, the ninth spin-off for IRB Barcelona, integrates multi-omic data to drive both biomedical research and clinical practice.

IRB Barcelona invites applications for two Group Leader positions, one in Chemical Biology and one in Structural Biology, as part of its strategic effort to strengthen the molecular sciences.